Bosman A R, Goldberg B, McKechnie J K, Offermeier J, Oosthuizen O J
S Afr Med J. 1977 Jan 15;51(3):57-61.
Ninety-three patients diagnosed as essential hypertensives, WHO stage I or II, entered this double-blind trial comparing 2 dose levels of CGP 2175-H 93/26 (metoprolol) with 2 doses of propranolol. Treatment on active medication was maintained for 6 weeks and was started after a 2-week washout and a 2-week placebo period. Twelve patients dropped out of the trial for reasons not related to the drugs and 1 patient was regarded as a therapeutic failure. Efficacy was assessed by measuring the diastolic and systolic blood pressure, pulse rate and by noting any significant ECG changes. All treatments reduced and maintained a lower blood pressure. However, a reduction with 360 mg propranolol per day was not statistically significant. Metoprolol 120 mg/d was significantly superior to propranolol 240 mg/d in holding the diastolic supine blood pressure at less than or equal to 90 mmHg. Metoprolol 120 mg/d and 210 mg/d pooled results were significantly superior to the propranolol 240 mg/d and 360 mg/d pooled data in maintaining a diastolic blood pressure of less than or equal to 90 mmHg. All treatments were well tolerated and in no case was it necessary to withdraw owing to adverse effects. No significant difference was detected between the treatments with respect to therapeutic emergent symptoms and signs. Laboratory results remained normal with all treatments.
93名被诊断为原发性高血压（WHO分期为I期或II期）的患者进入了这项双盲试验，该试验比较了2种剂量水平的CGP 2175-H 93/26（美托洛尔）与2种剂量的普萘洛尔。在经过2周的洗脱期和2周的安慰剂期后，开始进行为期6周的活性药物治疗。12名患者因与药物无关的原因退出试验，1名患者被视为治疗失败。通过测量舒张压和收缩压、脉搏率以及记录任何显著的心电图变化来评估疗效。所有治疗均降低并维持了较低的血压。然而，每天服用360mg普萘洛尔的降压效果在统计学上并不显著。在使仰卧位舒张压维持在小于或等于90mmHg方面，120mg/d的美托洛尔显著优于240mg/d的普萘洛尔。在维持舒张压小于或等于90mmHg方面，120mg/d和210mg/d美托洛尔的合并结果显著优于240mg/d和360mg/d普萘洛尔的合并数据。所有治疗的耐受性良好，无一例因不良反应而停药。在治疗引起的症状和体征方面，各治疗组之间未检测到显著差异。所有治疗的实验室检查结果均保持正常。
